Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US medtech, biotech companies still concerned with revised patent reform bill

This article was originally published in RAJ Devices

Executive Summary

Legislation to reform US patent law has been revised and reintroduced in the House of Representatives and the Senate1,2. The Patent Reform Act of 2009 continues to draw stiff opposition from the medtech, biotech and pharmaceutical industry associations, despite attempts by lawmakers to address their concerns and make improvements to the previous version of the act that was introduced in the previous Congress.

Advertisement
Advertisement
UsernamePublicRestriction

Register

SC095680

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel